GlassScriptPhysician profile
Sunil Badami
NPI 1003269085
$910.25
in general payments reported to CMS, 2019-2025
15 companies · $185 in 2025
The $185 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.66 · 2021: $336 · 2022: $142 · 2023: $190 · 2024: $42.56 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $417.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epizyme, INC. | $196.67 | 2021 | |
| Merck Sharp & Dohme LLC | $180.00 | 2022-2025 | Lynparza, Keytruda, Keytruda Qlex |
| E.R. Squibb & Sons, L.L.C. | $97.75 | 2022-2025 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $94.90 | 2021 | |
| Novartis Pharmaceuticals Corporation | $81.53 | 2023-2024 | |
| Eisai INC. | $61.44 | 2021-2022 | |
| Amgen INC. | $47.26 | 2021-2022 | |
| Pharmaessentia USA Corporation | $27.49 | 2025 | Besremi |
| Abbvie INC. | $23.01 | 2023 | Venclexta |
| Janssen Biotech, INC. | $20.69 | 2025 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $20.04 | 2025 | |
| Rigel Pharmaceuticals, INC. | $16.80 | 2022 | |
| Astellas Pharma US INC | $16.06 | 2022 | |
| Genentech USA, INC. | $14.66 | 2019 | |
| Seagen INC. | $11.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Badami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.